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Background: Mycoplasma fermentans has been associated with respiratory, genitourinary tract infections and
rheumatoid diseases but its role as pathogen is controversial. The purpose of this study was to probe that
Mycoplasma fermentans is able to produce respiratory tract infection and migrate to several organs on an
experimental infection model in hamsters. One hundred and twenty six hamsters were divided in six groups (A-F)
of 21 hamsters each. Animals of groups A, B, C were intratracheally injected with one of the mycoplasma strains:
Mycoplasma fermentans P 140 (wild strain), Mycoplasma fermentans PG 18 (type strain) or Mycoplasma pneumoniae
Eaton strain. Groups D, E, F were the negative, media, and sham controls. Fragments of trachea, lungs, kidney, heart,
brain and spleen were cultured and used for the histopathological study. U frequency test was used to compare
recovery of mycoplasmas from organs.
Results: Mycoplasmas were detected by culture and PCR. The three mycoplasma strains induced an interstitial
pneumonia; they also migrated to several organs and persisted there for at least 50 days. Mycoplasma fermentans
P 140 induced a more severe damage in lungs than Mycoplasma fermentans PG 18. Mycoplasma pneumoniae
produced severe damage in lungs and renal damage.
Conclusions: Mycoplasma fermentans induced a respiratory tract infection and persisted in different organs for
several weeks in hamsters. This finding may help to explain the ability of Mycoplasma fermentans to induce
pneumonia and chronic infectious diseases in humans.
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Mycoplasma fermentans was first isolated from the
lower genitourinary tract of humans in the early 1950’s.
Reports in the 1970’s of Mycoplasma fermentans in
joints of patients suffering rheumatoid arthritis (RA)
raised expectations for its role as pathogen [1,2]. When
AIDS appeared, interest about mycoplasmas increased,
species of the Class Mollicutes Mycoplasma fermentans,
Mycoplasma pirum and Mycoplasma penetrans were iso-
lated from AIDS patients. Several researches thought* Correspondence: lcedil9@gmail.com
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reproduction in any medium, provided the orthat mycoplasmas may act as cofactors in HIV associated
disease progression [3].
The role of mycoplasmas in RA is controversial. Early
work suggesting a link between Mycoplasma fermentans
and human RA was unconvincing because it was iso-
lated in a small proportion of patients, the bacteria was
rarely isolated from the genitourinary tract and there
was no evidence that it could colonize other sites [2].
The advent of polymerase chain reaction (PCR) provided
new insights. Thus by the use of PCR, Mycoplasma
fermentans has been found in the throat, peripheral
blood leucocytes and urine of HIV positive and HIV
negative patients [4]. More evidence has accumulated re-
cently to establish an important and emerging role for
Mycoplasma fermentans as pathogen in human respira-
tory tract and rheumatic diseases [1,2].
Presence of Mycoplasma fermentans in throat of
humans let us think about the possibility that the bacteriatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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eral organs, colonize them and persist there for several
weeks. We developed an animal model of respiratory tract
infection produced by Mycoplasma fermentans. Syrian
hamsters have several advantages over other laboratory
animals for evaluating the role of Mycoplasma fermentans
as pathogen that is the reason why they were chosen [5]
Animal models are particularly useful when the patho-
genic role of a microorganism is controversial.
The purpose of this study was to probe that Mycoplasma
fermentans is able to produce a respiratory tract infection
and migrate to several organs in hamsters.
Methods
Animals
One hundred and eighty six hamsters were included in
the study. Sixty hamsters were used to determine the
infecting dose and 126 animals to test the ability of
Mycoplasma to colonize and induce damage in the re-
spiratory tract and different organs.
Female and male hamsters weighing 100–200 g were
feed with chow and water “ad libitum”. Humidity,
temperature, lighting and ventilation were controlled dur-
ing the experiment. Animals were cared according to the
guide for the care and use of laboratory animals of the U.S
Department of Health and Human Services and Mexican
legislation for Care and Use of Laboratory Animals
(NOM-062-ZOO-199). Animals were cared in Claude
Bernard bioterio of the University. Dr. Carlos Escamilla
Weinman is the person who presides the committee for
use of laboratory animals in our university and he gave us
the approval for this study (BCB/PR/002/2010). Analgesics
and anesthetics were administered to animals in order to
avoid suffering. A throat swab of each animal was cultured
to check that they were not colonized by Mycoplasma
fermentans before the experiment began.
Strains
Three strains of mycoplasma were used in this study.
Mycoplasma fermentans P 140 isolated in our laboratory
from the respiratory tract of an asthmatic patient (12 pas-
sages in culture media). Mycoplasma pneumoniae Eaton
strain and Mycoplasma fermentans PG 18 isolated from
the genitourinary tract were kindly provided by Dr. Gail
H. Cassell from the University of Alabama at Birmingham
(number of passages in culture media unknown).
Strains were cultured in E media and kept frozen at
-70°C until used.
Determination of the infecting dose
Animals were injected with Ketamine 200 mg/ kg of
weight and pentobarbital 65 mg/kg of weight previous to
the inoculation.Sixty hamsters were used to determine the infecting
dose of mycoplasmas. Hamsters were divided in three
groups of 18 animals each (group I to III) and a control
group of 6 hamsters (group IV). Six hamsters of group I
were injected intratracheally with 0.1 ml of a culture that
contained 103 CFU/ml of Mycoplasma fermentans P 140,
six hamsters were injected with 0.1 ml of a culture that
contained 106 CFU of the same strain and the other six
hamsters were injected with 0.1 ml of a culture that
contained 109 CFU of the same strain. The same proced-
ure was repeated with the other strains Mycoplasma
fermentans PG 18 and Mycoplasma pneumoniae.
Six hamsters of group IV were not injected with myco-
plasmas neither ketofen and were considered negative
controls.
The day that hamsters were injected with mycoplas-
mas was considered day 0. Two hamsters of each group
were sacrificed on days 10, 20 and 40. Animals were
sacrificed by an injection of an overdose of sodium
pentobarbital. Two fragments of lung, trachea, kidney
and brain were cut one fragment of each organ was
deposited in 0.9 ml of E media, other two tenfold dilu-
tions were done to determine the presence of myco-
plasma in organs. The other fragment was fixed and
stained with hematoxylin and eosin to do a histopatho-
logical study. The same procedure was performed for
each dose and negative controls.
Inoculation with mycoplasmas
Animals were intramuscularly injected with Ketamine
(200 mg/kg of weight) and pentobarbital (65 mg/kg of
weight). Under aseptic conditions hamsters were intra-
tracheally injected using a syringe.
Animals were divided in six groups of 21 hamsters
each (group A-F). Hamsters of group A were intratra-
cheally injected with 0.1 ml of a culture that contained
106 CFU/ml of Mycoplasma fermentans P 140. Hamsters
of group B were injected with Mycoplasma fermentans
PG 18. Animals of group C were injected with Eaton
strain of Mycoplasma pneumoniae, hamsters of group D
were not injected with mycoplasmas. Hamsters of group
E were injected with 0.1 ml of E media and group F (sham
control) included animals that were stressed when they
were puncture with a needle but they were not injected
with mycoplasma or E media. All animals (controls and
infected) received the same drugs (analgesics and anes-
thetics) so they were submitted to the same stress.
Colonization of the respiratory tract and other organs
Three hamsters of each group (A to E) were sacrificed
on days 1, 5, 10, 15, 25, 35 and 50 after the inoculation.
Two fragments of 1 cm3 of trachea, kidney, lung,
heart, brain and spleen were cut. One fragment was cul-
tured in E media and the other was processed in a
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ple from each animal was cultured for mycoplasmas.Detection of mycoplasmas by culture
One fragment of each organ was cultured doing two ten-
fold dilutions in E media, each fragment was also cultured
in agar blood plates to isolate aerobic bacteria. Broths
were incubated at 37°C under aerobic conditions for
4 weeks or until the pH indicator of media turned yellow.
A blind passage of broths on E plates was done on day 10.
When the pH indicator of the media turned yellow a pas-
sage on E plates was done. Plates were incubated at 37°C
under aerobic conditions for 4 weeks or until growth
appeared. Positive cultures were identified as Mycoplasma
fermentans or Mycoplasma pneumoniae by PCR.Detection of mycoplasmas by PCR
Polymerase chain reaction test was performed in all broth
cultures (positive or negative) of different organs and in all
organs extracted (direct detection) of infected animals and
controls to detect the presence of Mycoplasma fermentans.
The oligonucleotide primers used for PCR assay were
50-GGACTATTGTCTAAACAATTTCCC-30 and 50-GGT
TATTCGATTTCTAAATCGCCT-30, each primer is 24 bp
long. This primer set flanks a 206-bp region in the M. fer-
mentans genome [6]. We confirmed the specificity of these
primers performing another PCR assay based on the ampli-
fication of the mycoplasmal 16S rRNA sequences published
by van Kuppeveld FJ, et al. and we obtained a 272 bp PCR
product, using the following primers: 5'-GAAGCCTTTC
TTCGCTGGAG-30 (forward primer) and 5'-ACAAAATC
ATTTCCTATTCTGTC-3' (reverse primer) [7].
The reaction mixture contained 50 mM KCl, 1.5 mM
MgCl2, 10 mM Tris–HCl (pH 8.3), 0.2 mM of each deoxy-
nucleotide triphosphate, 6 μM of each primer and 1 unit
of AmpliTaqW in a total volume of 50 μl. The sample to be
analyzed (5 μl) was always added last. A diluted lysate of
M. fermentans PG-18 corresponding to 100 CCU and
sterile water were used as positive and negative controls
respectively. The amplification involved 40 cycles, each
consisted of denaturation at 95°C for 25 s, primers anneal-
ing at 60°C for 60 s and extension at 72°C for 60 s. The
amplified products were analyzed by electrophoresis in 2%
agarose gels and visualized by UV light after ethidium
bromide staining.Table 1 Recovery of mycoplasmas from organs and blood of
Mycoplasma Trachea Right lung Left lung
M. fermentans P 140 11/21* 6/21 5/21
M. fermentans PG 18 2/21 6/21 3/21
M. pneumoniae 15/21 15/21 17/21
*Detected mycoplasmas in organs or blood/ total of infected hamsters.The oligonucleotide primers used for PCR detection of
Mycoplasma pneumoniae were MP5-1 (GAAGCTTATG
GTACAGGTTGG), MP5-2 (ATTACCATCCTTGTTGT
AAGG) [8].Results and discussion
Results
Three different doses of Mycoplasma fermentans P 140,
Mycoplasma fermentans PG 18 and Mycoplasma pneu-
moniae Eaton (103, 106, 109 CFU/ml) were tested in order
to infect the hamsters. The first doses 103 CFU/ml was
not able to induce an interstitial pneumonia, 106 CFU/ml
induced it while 109 CFU/ml induced a severe re-
spiratory tract infection. Results were very similar
using the three strains, so 106 CFU/ml was chosen as
the infective dose.
Table 1 shows positive cultures for mycoplasmas isolated
from different organs and blood. Mycoplasmas were iden-
tified by PCR. Mycoplasmas were recovered from all the
hamsters infected in at least one organ (trachea, lungs,
heart, spleen, kidney, brain or blood) during the whole ex-
periment. U frequency test was used to compare the recov-
ery of the three strains from organs (Table 1); there were
statistical differences between recovery of Mycoplasma
pneumoniae and Mycoplasma fermentans PG 18 or P 140.
Mycoplasma pneumoniae colonized all organs in a higher
proportion than Mycoplasma fermentans (p<0.05).
Mycoplasma fermentans P 140 was detected by culture
of organs along the experiment. Mycoplasmas colonized
trachea during all the experiment, the bacteria also
showed tropism to kidney and brain (Table 2).
Mycoplasma fermentans PG 18 colonized in a low rate
the respiratory tract (trachea and lungs), but the bacteria
showed tropism to spleen and kidney (Table 3).
Two hamsters were infected with the P 140 strain iso-
lated from a lung of a hamster sacrificed on day ten after
inoculation (second passage) another two hamsters were
infected with the PG18 strain isolated from a lung of a
hamster sacrificed on day ten after inoculation (second
passage). There was no difference in the severity of the
infection between animals infected with the first passage
and the ones infected with the second passage.
Mycoplasma pneumoniae infected in a high rate the
respiratory tract (trachea and lungs); it also showed trop-
ism to heart, spleen, kidney and brain (Table 4).experimentally infected hamsters
Heart Spleen Kidney Brain Blood
3/21 7/21 15/21 11/21 4/21
6/21 11/21 13/21 4/21 2/21
11/21 14/21 15/21 13/21 10/21
Table 2 Mycoplasma fermentans P 140 detection by culture and PCR in organs and blood of infected hamsters
Day Trachea Right lung Left lung Heart Spleen Kidney Brain Blood Total
1 1/3* 2/3 2/3 1/3 2/3 1/3 1/3 0/3 10/24
5 0/3 0/3 0/3 0/3 0/3 1/3 0/3 0/3 1/24
10 3/3 2/3 2/3 1/3 0/3 2/3 2/3 1/3 13/24
15 2/3 0/3 0/3 1/3 1/3 3/3 2/3 2/3 11/24
25 2/3 0/3 0/3 0/3 0/3 3/3 2/3 0/3 7/24
35 2/3 1/3 1/3 0/3 2/3 3/3 3/3 1/3 13/24
50 1/3 1/3 0/3 0/3 2/3 2/3 1/3 0/3 7/24
Total 11/21 6/21 5/21 3/21 7/21 15/21 11/21 4/21
*Detected mycoplasmas in organs or blood/ total of infected hamsters.
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Lungs showed bilateral diffuse condensation similar to an
interstitial pneumonia, few hemorrhagic areas without
pleural effusion. Mycoplasma pneumoniae (positive con-
trol) and Mycoplasma fermentans P 140 showed a severe
lesion. Mycoplasma fermentans PG 18 produced light lung
lesions. (Illustration 1). Mycoplasmas were recovered from
the infected lungs shown in the illustration 1.
Histopathological study
Mycoplasma fermentans PG 18 and P 140 induced an
interstitial pneumonia and tubular necrosis of the kidney
during the whole experiment, in all lung samples dam-
age increased slowly during the experiment until day 50.
Renal damage was more severe in samples from animals
infected with Mycoplasma fermentans PG 18.
Lung damage consisted of congestion of pulmonary
capillaries and presence of infiltration of mononuclear
cells in interstitial tissue (Table 5).
Mycoplasma fermentans P 140 induced a more severe
damage in lung than Mycoplasma fermentans PG 18
(Table 5). Mycoplasma pneumoniae produced an inter-
stitial pneumonia during the whole experiment, renal
damage was only observed from day 25 to 50.
No histopathological damage was observed in heart,
spleen and brain of hamsters infected with Mycoplasma
fermentans P 140, PG 18 and Mycoplasma pneumoniae.
No inflammatory response was observed in organs exceptTable 3 Mycoplasma fermentans PG18 detection by culture an
Day Trachea Right lung Left lung Heart
1 0/3* 2/3 1/3 2/3
5 0/3 1/3 0/3 1/3
10 0/3 1/3 0/3 0/3
15 0/3 1/3 0/3 0/3
25 1/3 0/3 0/3 0/3
35 1/3 0/3 1/3 2/3
50 0/3 1/3 1/3 1/3
Total 2/21 6/21 3/21 6/21
*Detected mycoplasmas in organs or blood/ total of infected hamsters.in lungs of hamsters infected with mycoplasmas (Figure 1).
Negative controls did not show damage in organs.
Detection of mycoplasmas by pcr
All cultures (positive or negative) and samples from
organs (direct detection) were searched for mycoplasmas
by PCR.
Also the PCR products were sequenced by the Sanger
method. We obtained a 99% to 100% homology with the
Mycoplasma fermentans sequences reported at nucleotide
blast service of the National Center for Biotechnology
Information (NCBI).
There was a correlation between cultures and direct
detection of mycoplasmas from organs. No mycoplasmas
were detected from controls.
Discussion
Mycoplasma fermentans isolated decades ago from the
urogenital tract has been implicated in several diseases
like rheumatoid arthritis and respiratory infections
[9,10]. Interest in this organism has increased because of
its possible role in the pathogenesis of rheumatoid arth-
ritis [11-14].
The purpose of this study was to test the ability of
Mycoplasma fermentans to induce a respiratory tract in-
fection and migrate to several organs.
Mycoplasma fermentans P 140 was chosen because it pro-
duced a severe respiratory tract infection in an asthmaticd PCR in organs and blood of infected hamsters
Spleen Kidney Brain Blood Total
3/3 2/3 2/3 0/3 12/24
2/3 1/3 0/3 1/3 6/24
0/3 2/3 1/3 0/3 4/24
0/3 0/3 0/3 0/3 1/24
3/3 3/3 0/3 1/3 8/24
2/3 2/3 0/3 0/3 8/24
1/3 3/3 1/3 0/3 8/24
11/21 13/21 4/21 2/21
Table 4 Mycoplasma pneumoniae detection by culture and PCR in organs and blood of infected hamsters
Day Trachea Right lung Left lung Heart Spleen Kidney Brain Blood Total
1 3/3 2/3 3/3 2/3 3/3 3/3 3/3 2/3 21/24
5 2/3 3/3 2/3 1/3 2/3 3/3 2/3 1/3 16/24
10 1/3 2/3 1/3 2/3 0/3 0/3 1/3 0/3 7/24
15 3/3 3/3 3/3 2/3 3/3 3/3 2/3 0/3 19/24
25 0/3 1/3 3/3 1/3 2/3 2/3 2/3 2/3 13/24
35 1/3 2/3 2/3 3/3 2/3 2/3 1/3 2/3 15/24
50 0/3 2/3 3/3 0/3 2/3 2/3 2/3 3/3 14/24
Total 10/21 15/21 17/21 11/21 14/21 15/21 13/21 10/21
*Detected mycoplasmas in organs or blood /total of infected hamsters.
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genitourinary tract and we supposed that it would not be
able to induce a severe respiratory tract infection.
Mycoplasma fermentans P 140 was able to infect the re-
spiratory tract and migrated to heart, spleen, kidney and
brain probably through blood in experimentally infected
hamsters. It was detected in a low amount in organs and
blood on day 5 probably because of an effective immune
response or because the bacteria is an intracellular organ-
ism. This strain was also able to persist in the respiratory
tract and organs until day 50.
Mycoplasma fermentans PG18 induced a less severe
respiratory tract infection even in animals inoculated
with a strain that was recovered from an infected ani-
mal; bacteria migrated to different organs and persisted
until day 50. It was not detected in organs or blood on
day 15. This strain was originally isolated from the geni-
tourinary tract probably the bacteria keeps its ability and
preference to colonize the genitourinary tract and this is
the reason why we isolated it in a higher percentage
from the kidney (where it produced a severe histopatho-
logical damage) than the respiratory tract.Table 5 Severity of histopathological damage observed in
lungs during the experiment
Day M. fermentans P 140 M. fermentans PG 18 M. pneumoniae
1 - - -
5 + - ++
10 +++ + +++
15 ++ + +++
25 ++ + ++
35 ++ ++ ++
50 ++ ++ ++
Score:
- No damage in 100% of 10 fields observed.
+ Interstitial tissue infiltrated with inflammatory cells in less than 30% of 10
fields observed.
++ Interstitial tissue infiltrated with inflammatory cells in 30–60% of 10 fields
observed.
+++ Interstitial tissue infiltrated with inflammatory cells in more than 60% of
10 fields observed.Mycoplasma pneumoniae was used as a positive control,
this bacterium is one of the main causes of atypical pneu-
monia, it has been associated to pharyngitis, bronchitis,
asthma, bronchiolitis, acute respiratory distress syndrome,
acute chest syndrome, pericarditis, meningoencephalitis
and arthritis [15-17]. Mycoplasma pneumoniae induced a
severe respiratory tract infection in hamsters, migrated
through blood and persisted during the whole experiment
in the respiratory tract and different organs. Histopatho-
logical damage was only observed in lungs and trachea.Figure 1 Lung damage produced by mycoplasma infection.
Macroscopic appearance of lungs A. Control (uninfected hamster),
B. hamster inoculated with Mycoplasma pneumoniae, C. hamster
inoculated with Mycoplasma fermentans PG18 and D. hamster infected
with Mycoplasma fermentans P 140. Animals infected
(B, C, D) were injected with 0.1 ml of 106 CFU/ml of a culture of
mycoplasmas. Mycoplasmas were recovered from the infected lungs.
Yáñez et al. BMC Research Notes 2013, 6:9 Page 6 of 7
http://www.biomedcentral.com/1756-0500/6/9Mycoplasma fermentans P 140 was detected in a higher
frequency from the respiratory tract than Mycoplasma
fermentans PG18 (22 animals versus 11 animals). Severe
damage in lungs of hamsters infected with Mycoplasma
fermentans P 140 was observed. Mycoplasma fermentans
PG18 induced mild damage in lungs (illustration 1).
Severe damage appeared on day 10 in animals infected
with P 140 strain while mild damage appeared on day 35
in lungs of hamsters infected with PG 18 strain. PG18
strain did not recover its virulence after one passage
through an animal.
These facts suggested us that P 140 strain is more
virulent than PG 18 strain.
All inoculated animals showed signs of infection (evi-
denced by recovery of the microorganism, detection of
mycoplasma by PCR or histopathological damage). In
some cases we detect the mycoplasma from all organs but
in other cases from at least one organ. Mycoplasmas were
not detected from controls.
This study showed the ability of Mycoplasma fermentans
to persist in different organs for at least 50 days after in-
oculation, probably because they can evade the immune
system and enter the cells where the antibodies and anti-
biotics cannot act and induce a chronic inflammation [18].
Intensive studies have been done in order to understand
the strategy used by Mycoplasma fermentans to interact
with host cells and evade the host protection system. The
finding that some mycoplasmas can reside intracellularly
helps to explain the development of chronic infectious dis-
eases produced by mycoplasmas [19]. It has also been
shown that mycoplasmas possess an impressive ability to
maintain a surface architecture that is antigenically and
functionally versatile and enable mycoplasmas to rapidly
chance their antigenic characteristics [11]. These variable
surface antigens undoubtedly contribute to the implication
of Mycoplasma fermentans in chronic infections [11].
The ability of mycoplasmas to persist in organs and in-
duce a chronic or even a latent infection may have impli-
cations in extrarrespiratory tract infections. Mycoplasmas
can grow silently in close interaction with mammalian
cells for a long period of time. However, prolonged inter-
actions with mycoplasmas through a gradual and progres-
sive course significantly affect many biologic properties of
mammalian cells [20].
It has been shown that mycoplasmas need to be con-
sidered as a potential factor in the genesis of chronic in-
flammatory diseases. Mycoplasma fermentans serves as a
stimulus for the production of several immune modulat-
ing cytokines and components of an inflammatory re-
sponse. Mycoplasma may modulate inflammatory and
immune processes within the lung as well as potentiate
T cell dependent immunopathologies [18].
The role as pathogen of Mycoplasma fermentans has been
controversial, it has been associated with genitourinarytract infections, rheumatic diseases and respiratory tract
infections and it has also been considered as normal flora.
Animal models of infection are particularly useful when the
role as a pathogen of a microorganism is controversial. We
choose Syrian hamsters to probe the ability of Mycoplasma
fermentans to induce a respiratory tract infection because
the histopathological changes produced by the infection re-
semble those that occur in natural human disease.
Mycoplasma fermentans produced pneumonia in ham-
sters and persisted in different organs for 50 days.
Conclusions
The main contribution of this study was to show the ability
of Mycoplasma fermentans to induce respiratory tract in-
fection and its persistence in different organs in hamsters.
This study also showed the ability of Mycoplasma
fermentans to migrate through blood, persist in several
organs and help us answering the question about the per-
sistence of viable mycoplasmas for weeks and the possibil-
ity that bacteria may induce chronic inflammation.
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